Comparative Pharmacology
Head-to-head clinical analysis: BACIGUENT versus BACTROBAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACIGUENT versus BACTROBAN.
BACIGUENT vs BACTROBAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacitracin inhibits bacterial cell wall synthesis by dephosphorylating the lipid carrier that transports peptidoglycan precursors across the cell membrane, leading to accumulation of toxic intermediates and cell lysis.
Binds to isoleucyl-tRNA synthetase, inhibiting bacterial protein synthesis.
Topical: Apply thin layer to affected area 1 to 3 times daily; maximum duration of therapy is 1 week.
Mupirocin (Bactroban) 2% ointment or cream applied topically to affected area three times daily for 5 to 14 days. For intranasal use: 0.5 g of 2% ointment applied to each nostril twice daily for 5 days.
None Documented
None Documented
Terminal elimination half-life approximately 2.5–3.5 hours in adults with normal renal function; prolonged in renal impairment (up to 20–30 hours in anuria)
Terminal elimination half-life: 1-1.5 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in end-stage renal disease)
Primarily renal excretion of unchanged drug via glomerular filtration and tubular secretion; >90% of absorbed dose recovered in urine within 24 hours; biliary/fecal elimination minimal (<2%)
Renal (90-95% unchanged), with minor biliary/fecal elimination (<5%)
Category C
Category C
Topical Antibiotic
Topical Antibiotic